Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234454 | 0.92 | LMNA (0.62) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL8775653 | 0.88 | LMNA (0.59) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL344303 | 0.87 | NPC1 (0.59) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL3068668 | 0.86 | LMNA (0.57) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL2295789 | 0.85 | CA12 (0.66) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL11388818 | 0.85 | ALDH1A1 (0.58) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL7355501 | 0.85 | ALDH1A1 (0.63) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL2185920 | 0.85 | CA12 (0.58) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL8815917 | 0.85 | SLC6A2 (0.61) | NPC1RAB9ALMNASMN1; SMN2CA12 | |
| SCHEMBL308290 | 0.85 | ALDH1A1 (0.63) | NPC1RAB9ALMNASMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) | 2014-02-20 | — | — | US | claimed |
| EP-1797068-B1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORP (US) | 2013-10-09 | — | — | EP | claimed |
| US-7863451-B2 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| CN-101080400-A | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORP (US) | 2007-11-28 | — | — | CN | claimed |
| EP-1797068-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006028964-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINES | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | CELGENE CORPORATION | 2006-03-09 | — | — | US | claimed |
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | claimed |
| WO-2002044144-A2 | NUCLEOPHILIC APPROACH FOR PREPARING RADIOLABELED IMAGING AGENTS AND ASSOCIATED COMPOUNDS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2002-06-06 | — | — | WO | claimed |
| EP-4619374-A1 | SYNTHESIS OF A-BETA-UNSATURATED CARBONYLS FROM ALKENES VIA SULFONIUM INTERMEDIATES AND THEIR APPLICATION IN THE SYNTHESIS OF CONJUGATED DIENE PHEROMONES, KAIROMONES, AND RELATED COMPOUNDS | HUN-REN TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2025-09-24 | — | — | EP | disclosed |
| EP-4480537-A2 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024105421-A1 | SYNTHESIS OF α,β-UNSATURATED CARBONYLS FROM ALKENES VIA SULFONIUM INTERMEDIATES AND THEIR APPLICATION IN THE SYNTHESIS OF CONJUGATED DIENE PHEROMONES, KAIROMONES, AND RELATED COMPOUNDS | Természettudományi Kutatóközpont (HU) | 2024-05-23 | — | — | WO | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
| US-5508432-A | TREATING GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5380872-A | Appetite suppresant, gall bladder disorders, CNS disorders | GLAXO INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0173522-B1 | PROCESS AND INTERMEDIATES FOR SORBINIL | PFIZER INC. (US) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034246-A1 | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds | SNCA, PARK7, SAMHD1 | NPC1 344/4885RAB9A 54/4885LMNA 3586/4885 |
| US-20060052609-A1 | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines | TNF, IL1A, TRAF2 | NPC1 2170/4885RAB9A 3887/4885LMNA 2234/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | NPC1 3374/4885RAB9A 2146/4885LMNA 3987/4885 |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | NSUN2, RNGTT, RNMT | NPC1 3669/4885RAB9A 2348/4885LMNA 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.